Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

It is widely understood that employing debt to fund operations can act as a powerful financial tool. But debt doesn ...

Regeneron Pharmaceuticals Inc. research and ratings by Barron's. View RGO revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Argus downgraded Regeneron Pharmaceuticals from a buy to a hold rating in its latest research report, signaling caution.

There are 16 changes to RBC’s Top 30 Global Ideas list of high conviction analyst stock picks with a long-term focus, ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...